 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 December 1998 | Volume 129 Issue 11 Part 2 | Pages 932-939
The complications of iron overload in hemochromatosis can be avoided by early diagnosis and appropriate management.Therapeutic phlebotomy is used to remove excess iron and maintain low normal body iron stores, and it should be initiated in men with serum ferritin levels of 300 µg/L or more and in women with serum ferritin levels of 200 µg/L or more, regardless of the presence or absence of symptoms. Typically, therapeutic phlebotomy consists of 1) removal of 1 unit [450 to 500 mL] of blood weekly until the serum ferritin level is 10 to 20 µg/L and 2) maintenance of the serum ferritin level at 50 µg/L or less thereafter by periodic removal of blood. Hyperferritinemia attributable to iron overload is resolved by therapeutic phlebotomy. When applied before iron overload becomes severe, this treatment also prevents complications of iron overload, including hepatic cirrhosis, primary liver cancer, diabetes mellitus, hypogonadotrophic hypogonadism, joint disease, and cardiomyopathy. In patients with established iron overload disease, weakness, fatigue, increased hepatic enzyme concentrations, right upper quadrant pain, and hyperpigmentation are often substantially alleviated by therapeutic phlebotomy. Patients with liver disease, joint disease, diabetes mellitus and other endocrinopathic abnormalities, and cardiac abnormalities often require additional, specific management. Dietary management of hemochromatosis includes avoidance of medicinal iron, mineral supplements, excess vitamin C, and uncooked sea-foods. This can reduce the rate of iron reaccumulation; reduce retention of nonferrous metals; and help reduce complications of liver disease, diabetes mellitus, and Vibrio infection. This comprehensive approach to the management of hemochromatosis can decrease the frequency and severity of iron overload, improve quality of life, and increase longevity.
Author and Article Information
From Southern Iron Overload Disorders Center, Birmingham, Alabama; Centers for Disease Control and Prevention, Atlanta, Georgia; London Health Sciences Centre, London, Ontario, Canada; Hopital Universitaire Pontchaillou, Rennes, France; University of Queensland, Brisbane, Australia; University of Utah College of Medicine and LDS Hospital, Salt Lake City, Utah; University of Kansas Medical Center, Kansas City, Kansas; and University of Washington, Seattle, Washington.
DIAGNOSIS AND MANAGEMENT
Management of Hemochromatosis
*The Hemochromatosis Management Working Group also includes Linda Cocchiarella, MD, MSc; James S. Dooley, MD; Vincent Fellitti, MD; David Brandhagen, MD; Victor Herbert, MD, JD; and Margit A. Krikker, MD.
Acknowledgments: The authors thank Dr. Anne C. Looker of the National Center for Health Statistics for reviews of data on age, sex, and serum iron variables from the National Health and Nutrition Examination Survey.
Grant Support: In part by Maternal and Child Health Branch, Division of Nutrition, Centers for Disease Control and Prevention (Atlanta, Georgia) and Southern Iron Disorders Center (Birmingham, Alabama).
Requests for Reprints: James C. Barton, MD, Southern Iron Disorders Center, Suite G-105, 2022 Brookwood Medical Center Drive, Birmingham, AL 35209; e-mail, ironmd{at}mem.po.com.
Current Author Addresses: Dr. Barton: Southern Iron Overload Disorders Center, suite G-105, 2022 Brookwood Medical Center Drive, Birmingham, AL 35209.
Dr. McDonnell: Centers for Disease Control and Prevention, Division of Nutrition and Physical Activity, 4770 Buford Highway Mailstop K-25, Atlanta, GA 30341-3724.
Dr. Adams: Department of Medicine, London Health Sciences Centre, University Campus, 339 Windermere Road, PO Box 5339, London, Ontario N6A 5A5, Canada.
Dr. Brissot: Clinique des Maladies du Foie, Unite INSERM U49, Hopital Universitaire Pontchaillou, 35033 Rennes, France.
Dr. Powell: The University of Queensland, Queensland Institute of Medical Research, The Bancroft Center, 300 Herston Road, Brisbane 4029 QLD, Australia.
Dr. Edwards: Department of Medicine, University of Utah College of Medicine and LDS Hospital, Outpatient Clinic, 325 8th Avenue, Salt Lake City, UT 84143.
Dr. Cook: Division of Hematology, University of Kansas Medical Center, 39th and Rainbow, Kansas City, KS 66103.
Dr. Kowdley: Division of Gastroenterology and Hepatology, RG-24, University of Washington, Seattle, WA 98195.
Note: This article is one of a series of articles comprising an Annals of Internal Medicine supplement entitled "Iron Overload, Public Health, and Genetics." To view a complete list of the articles included in this supplement, please view its Table of Contents.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  T. F. Reardon and D. G. Allen Iron injections in mice increase skeletal muscle iron content, induce oxidative stress and reduce exercise performance Exp Physiol, June 1, 2009; 94(6): 720 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reynolds, L. Stoddard, I. Bespalov, and A. Zhitkovich Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: linkage to DNA breaks in G2 phase by mismatch repair Nucleic Acids Res., January 28, 2007; 35(2): 465 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chung, J. Misdraji, and D. V. Sahani Case 33-2006 -- A 43-Year-Old Man with Diabetes, Hypogonadism, Cirrhosis, Arthralgias, and Fatigue N. Engl. J. Med., October 26, 2006; 355(17): 1812 - 1819. [Full Text] [PDF]
|
|
|
|
 |
|
 P.-A. Krayenbuehl, F. E. Maly, M. Hersberger, P. Wiesli, A. Himmelmann, K. Eid, P. Greminger, W. Vetter, and G. Schulthess Tumor Necrosis Factor-{alpha} -308G>A Allelic Variant Modulates Iron Accumulation in Patients with Hereditary Hemochromatosis Clin. Chem., August 1, 2006; 52(8): 1552 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Blanck, M. E Cogswell, C. Gillespie, and M. Reyes Iron supplement use and iron status among US adults: results from the third National Health and Nutrition Examination Survey Am. J. Clinical Nutrition, November 1, 2005; 82(5): 1024 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schmitt, R. M. Golub, and R. Green Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians Ann Intern Med, October 4, 2005; 143(7): 522 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.K. Limdi and J.R. Crampton Hereditary haemochromatosis QJM, June 1, 2004; 97(6): 315 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Hover, S. M. McDonnell, and W. Burke Changing the Clinical Management of Hereditary Hemochromatosis: Translating Screening and Early Case Detection Strategies Into Clinical Practice Arch Intern Med, May 10, 2004; 164(9): 957 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Mainous III, B. Wells, P. J. Carek, J. M. Gill, and M. E. Geesey The Mortality Risk of Elevated Serum Transferrin Saturation and Consumption of Dietary Iron Ann. Fam. Med, March 1, 2004; 2(2): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Premkumar and C. L. Bowlus Ascorbic Acid Does Not Increase the Oxidative Stress Induced by Dietary Iron in C3H Mice J. Nutr., February 1, 2004; 134(2): 435 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Lloyd, V. F. Reyna, and P. Whalen Accuracy and Ambiguity in Counseling Patients About Genetic Risk Arch Intern Med, November 12, 2001; 161(20): 2411 - 2413. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Sanchez, G. B. Schreiber, J. Bethel, P. R. McCurdy, S. A. Glynn, A. E. Williams, R. Gilcher, and for the Retrovirus Epidemiology Donor Study Prevalence, Donation Practices, and Risk Assessment of Blood Donors With Hemochromatosis JAMA, September 26, 2001; 286(12): 1475 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Hanson, G. Imperatore, and W. Burke HFE Gene and Hereditary Hemochromatosis: A HuGE Review Am. J. Epidemiol., August 1, 2001; 154(3): 193 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Steinberg, M. E. Cogswell, J. C. Chang, S. P. Caudill, G. M. McQuillan, B. A. Bowman, L. M. Grummer-Strawn, E. J. Sampson, M. J. Khoury, and M. L. Gallagher Prevalence of C282Y and H63D Mutations in the Hemochromatosis (HFE) Gene in the United States JAMA, May 2, 2001; 285(17): 2216 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Brittenham, H. G. Klein, J. P. Kushner, and R. S. Ajioka Preserving the National Blood Supply Hematology, January 1, 2001; 2001(1): 422 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J Seamark, M. Hutchinson, I. Heath, and M F McMullin Controversy in primary care: Should asymptomatic haemochromatosis be treated? Treatment can be onerous for patient and doctor Commentary: False certainty of clinical guidance Commentary: Early treatment is essential BMJ, May 13, 2000; 320(7245): 1314 - 1317. [Full Text]
|
|
|
|
|
|
H. B. El-Serag, J. M. Inadomi, and K. V. Kowdley Screening for Hereditary Hemochromatosis in Siblings and Children of Affected Patients: A Cost-Effectiveness Analysis Ann Intern Med, February 15, 2000; 132(4): 261 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Brittenham, G. Weiss, P. Brissot, F. Laine, A. Guillygomarc'h, D. Guyader, R. Moirand, and Y. Deugnier Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism Hematology, January 1, 2000; 2000(1): 39 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Andrews Disorders of Iron Metabolism N. Engl. J. Med., December 23, 1999; 341(26): 1986 - 1995. [Full Text] [PDF]
|
|
|
|
|
|
V. Herbert Hemochromatosis and Vitamin C Ann Intern Med, September 21, 1999; 131(6): 475 - 476. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rolfs and M. A Hediger Metal ion transporters in mammals: structure, function and pathological implications J. Physiol., July 1, 1999; 518(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Levine, S. C. Rumsey, R. Daruwala, J. B. Park, and Y. Wang Criteria and Recommendations for Vitamin C Intake JAMA, April 21, 1999; 281(15): 1415 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Cogswell, S. M. McDonnell, M. J. Khoury, A. L. Franks, W. Burke, and G. Brittenham Iron Overload, Public Health, and Genetics: Evaluating the Evidence for Hemochromatosis Screening Ann Intern Med, December 1, 1998; 129(11_Part_2): 971 - 979. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. McDonnell, D. L. Witte, M. E. Cogswell, and R. McIntyre Strategies To Increase Detection of Hemochromatosis Ann Intern Med, December 1, 1998; 129(11_Part_2): 987 - 992. [Abstract] [Full Text]
|
|
